Moderately Suspicious Thyroid Nodule (TIRADS/TR4): Do You Really Need a Biopsy?

Written by John P. Sabra, MD FACS
Updated May 2026

Educational only. This article is not medical advice. Always consult your physician about your individual situation.

If your ultrasound report says TIRADS 4 (or TR4) and your doctor has mentioned a biopsy, you are probably asking one of two questions: why does this nodule need a biopsy at all, or is there any way to avoid it? Both are fair questions, and both deserve honest, direct answers.

Here is the most important thing to understand: most TR4 nodules turn out to be benign. The biopsy is not a signal that your doctor thinks you have cancer; it is the test used to confirm that you do not.

What TIRADS 4 Actually Means

A nodule earns a TR4 designation when it accumulates 4, 5, or 6 points on the ACR TIRADS scoring system, based on five ultrasound features: composition, echogenicity, shape, margin characteristics, and the presence of echogenic foci such as microcalcifications. That point range translates to an estimated malignancy risk of roughly 6 to 17%.

Even at the upper boundary of TR4, roughly 83% of nodules turn out to be benign. The purpose of biopsy is to identify the minority that are not, and to give the majority a clear answer so they can stop wondering.

Where TR4 Fits in the TIRADS Picture

Level	Description	Malignancy Risk	ACR Guideline FNA Threshold
TR1	Benign	0%	Not typically indicated
TR2	Not suspicious	<1%	Not typically indicated
TR3	Mildly suspicious	~5%	Consider FNA at ≥ 2.5 cm
TR4 ▶	Moderately suspicious	6–17%	Consider FNA at ≥ 1.5 cm — patient factors may shift this
TR5	Highly suspicious	20–35%+	Consider FNA at ≥ 1.0 cm

The Size Threshold and Why It Is Only Part of the Picture

FNA biopsy is generally recommended for TR4 nodules that are 1.5 cm or larger. For TR4 nodules below that size, the standard starting point is surveillance: follow-up ultrasound at years 1, 2, 3, and 5.

TR4 nodule at 2.0 cm: Biopsy is generally recommended per current guidelines.
TR4 nodule at 1.2 cm: Surveillance is the typical starting approach. If there are other factors such as rapid growth, new symptoms, or patient preference for certainty, your physician may recommend biopsy anyway.
TR4 nodule at exactly 1.5 cm: This is the threshold conversation. Age, health status, symptoms, and your own priorities all factor into how your physician weighs the decision.

Do I Have Cancer? The Direct Answer

The majority of TR4 nodules, even those that proceed to biopsy, come back benign. A benign FNA result essentially rules out cancer at that time — carrying a residual false-negative rate of only around 1 to 3% — and transitions you to a routine surveillance schedule with no further intervention required.

The biopsy is not an assumption of cancer. It is the test that lets you stop wondering.

What FNA Biopsy Actually Involves

FNA stands for Fine Needle Aspiration. A thin needle is guided by real-time ultrasound into the nodule to withdraw a small sample of cells for pathology review. The procedure takes approximately 20 to 30 minutes, requires no general anesthesia, and does not require hospital admission.

Positioning: You lie on your back with your neck gently extended.
Local anesthetic: A small amount of lidocaine is injected at the skin surface. Most patients feel a brief sting, after which the area is numb.
Needle passes: Two to four passes are made through the nodule to collect enough cells. Each pass takes only a few seconds.
Completion: Firm pressure is applied for several minutes. No incision, no stitches. Most patients return to normal activities the same day.

Results are categorized using the Bethesda classification system and typically return within three to seven business days.

When Biopsy May Reasonably Be Deferred

Nodule below the 1.5 cm threshold: ACR guidelines support surveillance as the standard starting approach for smaller TR4 nodules.
Significant competing medical conditions: For patients with serious health issues, the risks of the procedure may genuinely outweigh the benefit of a tissue diagnosis.
Predominantly cystic nodule: FNA is less accurate for cystic nodules. A different management path is often more appropriate.
Recent benign biopsy of the same stable nodule: In a nodule with no change and no significant growth since a prior benign biopsy, the timing of repeat testing is a clinical conversation, not a mandatory step.
Patient preference for surveillance: For some patients with a small sub-threshold nodule and low overall risk, the choice to watch carefully is a legitimate, informed decision made in partnership with their physician.

What Happens After a TR4 Biopsy

Bethesda II: Benign (most common outcome): No cancer cells identified. The nodule transitions to routine surveillance with follow-up ultrasound at 12 to 24 months. For patients with a large symptomatic benign nodule, this result may open the door to non-surgical treatment such as RFA.
Bethesda III or IV: Indeterminate: The cells are not clearly benign and not clearly malignant. This happens in roughly 15 to 30% of biopsies. Molecular testing (Afirma or ThyroSeq) can frequently reclassify an indeterminate result as likely benign, avoiding surgery in many cases.
Bethesda V or VI: Suspicious or Malignant: Surgical referral is the standard next step. Thyroid cancer — particularly papillary thyroid carcinoma — carries a five-year survival rate exceeding 98% for most patients. This leads to a clear, well-established treatment pathway.

The Bottom Line for TR4 Patients

A TR4 result means your nodule has ultrasound features that warrant closer evaluation. It does not mean cancer is the likely outcome — the large majority of TR4 nodules are confirmed benign. But it does mean this is the right moment to build a care plan with a physician who specializes in thyroid disease.

The right plan depends on your nodule’s exact point total, its size, your overall health, and your treatment goals. That conversation cannot happen in a radiology report, and it cannot happen in an article.

References

This article was written byJohn P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. TIRADS categories are clinical guidelines, not mandatory rules. Individual nodule characteristics, patient health history, age, risk factors, and clinical judgment all determine the appropriate management for every patient.

Ready to Talk to a Specialist?

A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.

Find a Thyroid Specialist Near You →